Scholar Rock announced new preclinical data supporting the potential of SRK-439, a highly selective investigational anti-myostatin antibody, in cardiometabolic disorders. The data showed SRK-439's ability to increase lean mass and lower fat mass gain when administered with metformin.
SRK-439 is a novel anti-myostatin monoclonal antibody being advanced towards clinical development. This preclinical evidence suggests a promising role for Scholar Rock's myostatin-targeting technology in addressing muscle loss associated with weight management therapies.
This development expands Scholar Rock's strategic vision beyond spinal muscular atrophy, leveraging its expertise to address emerging challenges in cardiometabolic health. The company aims to create novel therapies for serious diseases by modulating growth factor signaling.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.